Furthermore, we examined the relationship between S100 expression and the clinicopathological features in the ovarian cancer patients, including pathologic grades, clinical stages and TP53 mutation status (Additional file 2: Table S7). This evidence concerns the gene TP53 and ovarian carcinoma.